Medicinal composition for treating B cell lymph tumour

Abstract

A composite medicine for treating B-cell leucoma is prepared from rituximab and suberoylanilide hydroxamic acid (SAHA). Its advantages are obvious synergistic effect, high curative effect and low cost.

Description

technical field [0001] The invention relates to a pharmaceutical composition for treating cancer, in particular to a pharmaceutical composition for treating B-cell lymphoma. Background technique [0002] Lymphoma is a kind of malignant tumor originating from lymphoid tissue. In recent years, the worldwide incidence rate has almost doubled, seriously endangering human health. B-cell lymphoma is the most common type of lymphoma, accounting for about 50-60% of lymphomas. Except for early-stage, localized, and low-grade B-cell lymphoma, which can be treated with radiotherapy alone, the current main treatment method is still combined chemotherapy. Combined chemotherapy can make about 50-60% of patients achieve disease remission, and 20-30% of patients achieve long-term survival, but most patients are ineffective or relapse rapidly after treatment, the disease progresses rapidly, and the prognosis is poor. More importantly, the side effects of chemotherapy are large, and patient...

AI Technical Summary

Problems solved by technology

However, the treatment cost of patients is expensive, and some patients develop drug resistance in the early stage of treatment or when the disease relapses

Images